WASM / Westmountain Company - Zgłoszenia SEC, Raport roczny, o pełnomocnictwie

REVOKED

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SECURITIES EXCHANGE ACT OF 1934 Release No. 92314 / July 1, 2021 Admin. Proc. File No. 3-19938 In the Matter of INVENTABIOTECH INC. OPINION OF THE COMMISSION SECTION 12(j) PROCEEDING Grounds for Remedial Action Failure to Comply with Periodic Filing Requirements Company failed to file periodic reports in violation of Section 13(a) of the Securiti

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2019 InventaBioTech Inc. (Exact name of Registrant as specified in its charter) Colorado 000-53030 26-1315305 (State or other jurisdiction of incorporation) (Commission

WASM / Westmountain Company NT 10-Q - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-53030 CUSIP NUMBER (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2019 ¨

WASM / Westmountain Company NT 10-Q - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-53030 CUSIP NUMBER (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2019 ¨ T

WASM / Westmountain Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-53030 CUSIP NUMBER (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2018

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2019 InventaBioTech Inc. (Exact name of Registrant as specified in its charter) Colorado 000-53030 26-1315305 (State or other jurisdiction of incorporation) (Commissio

NEITHER THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES

Exhibit 4.1 Exhibit A NEITHER THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES

Employment Agreement

Exhibit 10.2 Inventa 80Tcch Employment Agreement Title: Interim CEO at InventaBioTech. Employed Full Time and based in NY (no requirement to relocate to San Antonio). Note: The Interim CEO will to disclose his current Divine activities to allow him to carve out and continue these actives while functioning as a full time Inventa Biotech CEO. The position will require a board seat. Duration: Until a

all questions properly completed; a certified check, bank draft or money order, in the amount of the purchase price for the Notes to be purchased, payable to JPMorgan Chase Bank for "InventaBioTech Inc." Wired funds are also acceptable. The Company w

Exhibit 10.1 Subscription Agreement Number: January , 2019 Issued to: in connection with the Offering by InventaBioTech Inc. of A Minimum of $100,000.000 and a Maximum Principal Amount of $1,000,000 of Convertible Promissory Notes payable on bearing interest at the annual rate of 12% and convertible into equity securities of the Company as set forth in the Notes Placement Agent DIVINE CAPITAL MARK

EX-3

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of the Report (Date of earliest event reported): December 28, 2018 InventaBioTech Inc.

WASM / Westmountain Company DEF 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5

WASM / Westmountain Company PRE 14C

PRE 14C 1 wmcopre14c11202018.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission

ARTICLE IV. MISCELLANEOUS

Exhibit 10.2 THIS INSTRUMENT CONTAINS AN AFFIDAVIT OF CONFESSION OF JUDGMENT PROVISION WHICH CONSTITUTES A WAIVER OF IMPORTANT RIGHTS BORROWER MAY HAVE AND ALLOWS THE HOLDER TO OBTAIN A JUDGMENT AGAINST BORROWER WITHOUT ANY FURTHER NOTICE. NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTE

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November 8, 2018, by and between WESTMOUNTAIN COMPANY, a Colorado corporation, with headquarters located at 3463 Magic Drive, Suite 120, San Antonio, TX 78229 (the “Company”), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company, with its address at 1040 First

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of the Report (Date of earliest event reported): November 14, 2018 WESTMOUNTAIN COMPANY (Exact Name if Business Issuer as specified in its Charter) Colorado 000-53030 26-1315305 (State or other Jurisdiction of Incorporation) (Comm

an effective price per share less than the then Exercise Price (such lower price, the “Base Share Price” and such issuances collectively, a “Dilutive Issuance”) (if the holder of the Common Stock or Common Stock Equivalents so issued shall at any tim

Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE

WASM / Westmountain Company 10-Q/A (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment Number 1) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended September 30, 2018 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Issuer as s

WASM / Westmountain Company 10-Q (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended September 30, 2018 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Issuer as specified in its charter

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of the Report (Date of earliest event reported): November 5, 2018 WESTMOUNTAIN COMPANY (Exact Name if Business Issuer as specified in its Charter) Colorado 000-53030 26-1315305 (State or other Jurisdiction of Incorporation) (Commi

WASM / Westmountain Company 10-Q/A (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment 1) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended June 30, 2018 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Issuer as specified in

WASM / Westmountain Company 10-Q (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended June 30, 2018 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Issuer as specified in its charter) Col

WASM / Westmountain Company 10-Q (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended March 31, 2018 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Issuer as specified in its charter) Co

Financial Statements and Exhibits

FORM 8-K/A (Amendment No. 1) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of the Report (Date of earliest event reported): March 19, 2018 WESTMOUNTAIN COMPANY (Exact Name if Business Issuer as specified in its Charter) Colorado 0-53030 26-1315305 (State or other Jurisdiction of Incorporation) (C

CYTOBIOSCIENCE INC. Consolidated Financial Statements Years Ended December 31, 2017 and 2016

EX-99.1 3 ex991.htm Exhibit 99.1 CYTOBIOSCIENCE INC. Consolidated Financial Statements Years Ended December 31, 2017 and 2016 Page Report of Independent Registered Public Accounting Firm 1 Financial Statements Consolidated Balance Sheets 3 Consolidated Statements of Operations 4 Consolidated Statements of Comprehensive Loss 5 Consolidated Statements of Changes in Stockholders' Equity (Deficit) 6 C

WestMountain Company and CytoBioscience, Inc. Pro-Forma Condensed Consolidated Balance Sheet For the year ended December 31, 2017 (expressed in thousands of U.S. dollars)

Exhibit 99.2 Below are the pro-forma consolidated financials as of December 31, 2017 as if the acquisition closed on December 31, 2017: WestMountain Company and CytoBioscience, Inc. Pro-Forma Condensed Consolidated Balance Sheet For the year ended December 31, 2017 (expressed in thousands of U.S. dollars) WestMountain CytoBioscience Adjustments Pro Forma Combined Assets Cash and cash equivalents $

WASM / Westmountain Company NT 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-53030 CUSIP NUMBER 96110T101 (Check one): ☐Form 10-K o Form 20-F o Form 11-K ☒Form 10-Q o Form 10-D o Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition

WASM / Westmountain Company / BOCO Investments LLC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Amendment No. 1 Under the Securities Exchange Act of 1934 WESTMOUNTAIN COMPANY (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 per share (Title of Class of Securities) 96110T101 (CUSIP Number) Joseph Zimlich, 262 East Mountain Avenue, Fort Collins, Colorado 80524 (Name, Address and Telephone Number of Person Autho

WASM / Westmountain Company SC 14F1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14F-1 INFORMATION STATEMENT PURSUANT TO SECTION 14(f) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14f-1 THEREUNDER Commission File Number: 000-25053 WESTMOUNTAIN COMPANY (Exact Name if Business Issuer as specified in its Charter) Colorado 0-53030 26-1315305 (State or other Jurisdiction of Incorporation) (Commissio

Lock-up Agreement between WestMountain Company and the officers, directors and shareholders party thereto.

Exhibit 10.1 Lock-Up Agreement March 1, 2018 The undersigned hereby agrees that, without the prior written consent of Westmountain Company ("the Company"), the undersigned will not, during the period commencing on the date hereof and ending two years after the date hereof(the "Lock-Up Period "), (1) offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly o

Agreement of Merger and Plan of Reorganization dated as of March 19, 2018 by and among WestMountain Company, WASM Acquisition Corp. and CytoBioscience, Inc.

Exhibit 2.1 AGREEMENT OF MERGER AND PLAN OF REORGANIZATION among WESTMOUNTAIN COMPANY WASM ACQUISITION CORP. and CYTOBIOSCIENCE, INC. March 19, 2018 Exhibit 2.1 Merger Agreement - Page 1 AGREEMENT OF MERGER AND PLAN OF REORGANIZATION THIS AGREEMENT OF MERGER AND PLAN OF REORGANIZATION is made and entered into on March 19, 2018, by and among WESTMOUNTAIN COMPANY, a Colorado corporation ("Parent"),

Investment Banking Agreement dated December 15, 2017 between Registrant and Divine Capital Markets LLC.

Exhibit 10.3 Divine Capital Markets LLC Investment Banking Agreement Sent via email to [email protected] CytoBioscience Incorporated 3453 Magic Dr S 120 San Antonio, TX 79229 USA Attn: James Garvin, PhD Dear Dr. Garvin: The purpose of this letter agreement (this "Engagement Letter" or the "Agreement") is to set forth the terms and conditions pursuant to which Divine Capital Markets LLC (

Securities and Exchange Commission

EX-16.1 6 ex161.htm EMPLOYMENT SERVICES AGREEMENT - BOURG Exhibit 16.1 Securities and Exchange Commission 100 F Street, NE Washington, District of Columbia 20549 Re: Westmountain Company Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated March 23, 2018 of Westmountain Company and are in agreement with all statements made pertaining to EKS&H LLLP. We have no basis to agree or disagree w

CytoBioscience, Inc. Announces Merger With WestMountain Company

Exhibit 99.1 CytoBioscience, Inc. Announces Merger With WestMountain Company San Antonio, TX – (Accesswire) – March 23, 2018 – CytoBioscience, Inc. (the "Company"), a revenue-generating ion channel screening business providing medical instrumentation and research services to organizations in the pharmaceutical and drug research market, today announced that it has closed a merger (the "Merger") wit

Securities Purchase Agreement between WestMountain Company and the investor parties thereto.

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this "Agreement") is made as of the 26th day of February, 2018 by and among CytoBioscience, Inc., a Delaware corporation (the "Company"), and the purchasers identified on the signature page hereto (each a "Purchaser" and together the "Purchasers"). RECITALS WHEREAS, the Company desires to sell to the Purchasers, on a "b

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, ABS Informational and Computational Material, Changes in Registrant's Certifying Accountant, Completion of Acquisition or Disposition of Assets, Other Events

FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of the Report (Date of earliest event reported): March19, 2018 WESTMOUNTAIN COMPANY (Exact Name if Business Issuer as specified in its Charter) Colorado 0-53030 26-1315305 (State or other Jurisdiction of Incorporation) (Commission File Number

Amendment to Articles of Incorporation Increasing Authorized Common Shares

Exhibit 3.4 ARTICLE I Incorporation This attachment is incorporated into the foregoing Articles of Incorporation. ARTICLE II Authorized Shares Section 1: Number. The aggregate number of shares which the Corporation shall have authority to issue is One Hundred Million (100,000,000) Common Shares of one class, with unlimited voting rights, all with a par value of $0.001 per share and One Million (1,

WASM / Westmountain Company 10-K (Annual Report)

10-K 1 wmco10k12312017.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Small Business I

WASM / Westmountain Company 14C

SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [] Preliminary Information Statement [] Confidential, For Use of the Commission only (as permitted by Rule 14c-5(d)(2)) [ X ] Definitive Information Statement WESTMOUNTAIN COMPANY (Name of Registrant as Specified in Its Charter) Payment of Filing Fee (Check the appropriate box): [X] No Fee Required [] Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.

WASM / Westmountain Company 14C

SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [] Confidential, For Use of the Commission only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement WESTMOUNTAIN COMPANY (Name of Registrant as Specified in Its Charter) Payment of Filing Fee (Check the appropriate box): [X] No Fee Required [] Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.

Other Events

FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported) December 28, 2017 WESTMOUNTAIN COMPANY (Exact Name of Business Issuer as specified in its charter) Colorado 0-53030 26-1315305 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emp

WASM / Westmountain Company (Current Report)

FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported) December 18, 2017 WESTMOUNTAIN COMPANY (Exact Name of Business Issuer as specified in its charter) Colorado 0-53030 26-1315305 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emp

Other Events

FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported) November 30, 2017 WESTMOUNTAIN COMPANY (Exact Name of Business Issuer as specified in its charter) Colorado 0-53030 26-1315305 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emp

WASM / Westmountain Company 10-Q (Quarterly Report)

10-Q 1 wmco10q9302017.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended September 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Issuer

WASM / Westmountain Company 10-Q (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended June 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Issuer as specified in its charter) Co

Westmountain (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended March 31, 2017 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Issuer as specified in its charter) Co

Westmountain (Annual Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Small Business Issuer as specified in its c

Westmountain 0-K

FORM 12B-25 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File No.: 0-53030 CUSIP No.:96110T101 NOTIFICATION OF LATE FILING [X] Form 10-K [ ] Form 11-K [ ]Form 20-F [ ] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2016 Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a

Westmountain (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended September 30, 2016 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Issuer as specified in its charte

Westmountain 0-Q

FORM 12B-25 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File No.: 0-53030 CUSIP No.:96110T101 NOTIFICATION OF LATE FILING [ ] Form 10-K [ ] Form 11-K [ ]Form 20-F [X] Form 10-Q [ ] Form N-SAR For Period Ended: September 30, 2016 Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a

Changes in Registrant's Certifying Accountant

FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported) October 19, 2016 WESTMOUNTAIN COMPANY (Exact Name of EKS&Hall Business Issuer as specified in its charter) Colorado 0-53030 26-1315305 (State or other jurisdiction of incorporation) (Commission File Number)

September 28, 2016

EXHIBIT 16.1 September 28, 2016 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: WestMountain Company EIN: 26-1315305 Commissioners: We have read the statements under Item 4.01 of the Current Report on Form 8-K of WestMountain Company to be filed with the Securities and Exchange Commission on or about September 28, 2016. We agree with all statements pertaining to us.

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported) September 28, 2016 WESTMOUNTAIN COMPANY (Exact Name of EKS&Hall Business Issuer as specified in its charter) Colorado 0-53030 26-1315305 (State or other jurisdiction of incorporation) (Commission File Number

Westmountain (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended June 30, 2016 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Issuer as specified in its charter) Co

Westmountain (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended June 30, 2016 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Issuer as specified in its charter) Co

Westmountain (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended March 31, 2016 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Issuer as specified in its charter) Co

Westmountain 0-Q

FORM 12B-25 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File No.: 0-53030 CUSIP No.:96110T101 NOTIFICATION OF LATE FILING [ ] Form 10-K [ ] Form 11-K [ ]Form 20-F [X] Form 10-Q [ ] Form N-SAR For Period Ended: March 31, 2016 Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a por

Westmountain ANNUAL REPORT (Annual Report)

wasm10k12312013.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Small Business Issuer a

Westmountain 0-K

FORM 12B-25 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File No.: 0-53030 CUSIP No.:96110T101 NOTIFICATION OF LATE FILING [X] Form 10-K [ ] Form 11-K [ ]Form 20-F [ ] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2015 Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a

Westmountain ANNUAL REPORT (Annual Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-53030 WESTMOUNTAIN COMPANY (Exact Name of Small Business Issuer as specified in its char

Amendment to Articles of Incorporation

Exhibit 3.3

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported) February 27, 2014 WESTMOUNTAIN COMPANY (Exact Name of Small Business Issuer as specified in its charter) WestMountain Asset Management, Inc. (Previous Name of Small Business Issuer as specified in its charte

- DEF 14C

SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [] Confidential, For Use of the Commission only (as permitted by Rule 14c-5(d)(2)) [X Definitive Information Statement WESTMOUNTAIN ASSET MANAGEMENT, INC.

- PRE 14A

SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [] Confidential, For Use of the Commission only (as permitted by Rule 14c-5(d)(2)) [X Definitive Information Statement WESTMOUNTAIN ASSET MANAGEMENT, INC.

LETTER

September 18, 2013 Mr. Brian L. Klemsz Chief Executive Officer and President WestMountain Asset Management, Inc. 123 North College Ave, Ste 200 Fort Collins, Colorado 80524 Re: WestMountain Asset Management, Inc. Form 10-K for the year ended December 31, 2012 Filed on March 25, 2013 File No. 000-53030 Dear Mr. Klemsz: We have completed our review of your filings. We remind you that our comments or

-

WestMountain Asset Management, Inc. 123 North College Avenue, Ste 200 Fort Collins, CO 80524 September 13, 2013 Mr. Kevin Woody Branch Chief U.S. Securities and Exchange Commission 100 F Street, N. E. Washington, D.C. 20549 Re: WestMountain Asset Management, Inc. (the Company) Form 10K for the year ended December 31, 2012 Filed March 25, 2013 File Number: 000-53030 Dear Mr. Woody, This is in respo

LETTER

August 29, 2013 Mr. Brian L. Klemsz Chief Executive Officer and President WestMountain Asset Management, Inc. 123 North College Ave, Ste 200 Fort Collins, Colorado 80524 Re: WestMountain Asset Management, Inc. Form 10-K for the year ended December 31, 2012 Filed on March 25, 2013 File No. 000-53030 Dear Mr. Klemsz: We have reviewed your response letter dated August 21, 2013 and have the following

-

WestMountain Asset Management, Inc. 123 North College Avenue, Ste 200 Fort Collins, CO 80524 August 21, 2013 Mr. Kevin Woody Branch Chief U.S. Securities and Exchange Commission 100 F Street, N. E. Washington, D.C. 20549 Re: WestMountain Asset Management, Inc. (the Company) Form 10K for the year ended December 31, 2012 Filed March 25, 2013 File Number: 000-53030 Dear Mr. Woody, This is in response

LETTER

August 6, 2013 Mr. Brian L. Klemsz Chief Executive Officer and President WestMountain Asset Management, Inc. 123 North College Ave, Ste 200 Fort Collins, Colorado 80524 Re: WestMountain Asset Management, Inc. Form 10-K for the year ended December 31, 2012 Filed on March 25, 2013 File No. 000-53030 Dear Mr. Klemsz: We have reviewed your filing and have the following comments. In our comments, we ma

-

FORM 12B-25 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File No.: 0-53030 CUSIP No.:96110T101 NOTIFICATION OF LATE FILING [X] Form 10-K [ ] Form 11-K [ ]Form 20-F [ ] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2011 Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a